A 5-Year Retrospective Study on 200 Adults with ADHD, Autism, and AuDHD[cite: 1]
Modern psychiatry faces a quiet crisis: over 30% of individuals struggling with major depression do not respond to standard antidepressant medications. For decades, this has been labelled Treatment-Resistant Depression (TRD).
Our research exposes a systematic explanation for this failure: the treatment-resistant population heavily overlaps with the massive global gap of undiagnosed, late-identified neurodivergent adults. When an atypical nervous system experiencing chronic burnout from a lifetime of masking is treated with standard neurotypical protocols, the interventions fail.
This white paper details the clinical outcomes of a 5-year longitudinal study evaluating 200 neurodivergent adults (N=200) who underwent tailored 5-MeO-DMT protocols [cite: 1]. The data reveals that when fast-acting tryptamines are paired with neuro-affirming sensory optimisation and precise delivery routes, we can successfully cycle the nervous system out of chronic trauma loops where traditional daily pharmaceuticals fell short[cite: 1].
Important Notice: This document is intended solely for informational and educational purposes. It does not constitute medical advice or a clinical recommendation. The use of 5-MeO-DMT involves significant physiological and psychological risks and requires expert supervision. Practitioners must conduct independent research and consult local legal and medical regulations.
Our cohort data demonstrated robust, statistically significant reductions in mental health distress from baseline (T_0) to the 6-month post-treatment endpoint (T_2)[cite: 1]:
84% Depression Reduction: 168 participants achieved a clinically significant drop in PHQ-9 scores, moving from severe/moderate to mild/minimal ranges [cite: 1].
81% Anxiety Alleviation: Sustained reductions in generalised autonomic overdrive were tracked via the GAD-7 at the 6-month mark[cite: 1].
75% Trauma Remission: 150 out of 200 participants experienced a drastic decline in PCL-5 scores, no longer meeting the clinical diagnostic criteria for PTSD or C-PTSD[cite: 1].
80% Chronic Burnout Relief: Participants reported deep, lasting relief from the compounding effects of chronic autistic and ADHD burnout[cite: 1].
Our data exposed a striking pharmacodynamic variance: 90% of individuals with an ADHD profile required significantly higher saturation doses of 5-MeO-DMT via vaporised administration to achieve a complete breakthrough[cite: 1]. Due to atypical baseline dopamine and norepinephrine dynamics, these brains exhibit heightened top-down cognitive shielding[cite: 1]. Standard clinical doses often leave them stuck in a frustrating, hyper-aware state of cognitive resistance [cite: 1].
While unmetered inhalation carries a high risk of post-session reactivations (“flashbacks”), our data show that alternative administration modalities—specifically, sublingual solutions or stable 5-MeO-DMT succinate salts via subcutaneous (SC) or intramuscular (IM) injection—effectively eliminate this risk [cite: 1]. Slowing the absorption rate prevents sudden nervous system shock, providing an unshakeable transition for hypervigilant profiles [cite: 1].
To safely facilitate these breakthroughs, we replaced standard, cold clinical environments with a strict sensory-optimised framework[cite: 1]:
Ethics & Consent: Data were collected retrospectively from a naturalistic cohort[cite: 1]. All participants provided explicit, written informed consent for their anonymised psychometric metrics to be utilised for clinical research and publication[cite: 1].
Conflict of Interest: Author Lisa Silva is affiliated with Shangriballa, where data collection occurred[cite: 1]. This research is conducted in the interest of public data transparency; no financial incentives or commissions were tied to positive psychometric outcomes[cite: 1].
Bonnelle, V., et al. (2024). Autonomic nervous system activity correlates with peak experiences induced by DMT. Journal of Psychopharmacology[cite: 1].
Chmiel, J., et al. (2026). The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic Review. International Journal of Molecular Sciences[cite: 1].
Reckweg, J. T., et al. (2022). The clinical pharmacology and potential therapeutic applications of 5-MeO-DMT. Frontiers in Pharmacology[cite: 1].
Important Notice: This document is intended solely for informational and educational purposes. It does not constitute medical advice or a clinical recommendation. The use of 5-MeO-DMT involves significant physiological and psychological risks and requires expert supervision. Practitioners must conduct independent research and consult local legal and medical regulations.